New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 Apr 13

PMID 29649113

Citations 10

Authors

Monika Swierczewska

Andrzej Klejewski

Maciej Brazert

Dominika Kazmierczak

Dariusz Izycki

Michal Nowicki

Maciej Zabel

Radoslaw Januchowski

Affiliations

Soon will be listed here.

Abstract

Development of drug resistance is the main reason for low chemotherapy effectiveness in treating ovarian cancer. Paclitaxel (PAC) is a chemotherapeutic drug used in the treatment of this cancer. We analysed the development of PAC resistance in two ovarian cancer cell lines. Exposure of drug-sensitive cell lines (A2780 and W1) to PAC was used to determine the primary response. An established response was determined in PAC-resistant sublines of the A2780 and W1 cell lines. qRT-PCR was performed to measure the expression levels of specific genes. We observed decreased expression of the , and genes in the PAC-resistant cell lines. Short-term exposure to PAC led to increased expression of the and genes in the A2780 and W1 cell lines. In the A2780 cell line, we also observed increased expression of the gene and decreased expression of the and genes after PAC treatment. In the W1 cell line, short-term treatment with PAC upregulated the expression of the gene, a marker of Cancer stem cells (CSCs). Our results suggest that downregulation of the , , and genes and upregulation of the and genes may be related to PAC resistance.

Citing Articles

The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models.

Stasiak P, Sopel J, Lipowicz J, Rawluszko-Wieczorek A, Korbecki J, Januchowski R Int J Mol Sci. 2025; 26(3).

PMID: 39940891 PMC: 11817197. DOI: 10.3390/ijms26031124.

Clinical Efficacy of Fuzheng Guben Anticancer Decoction Combined with Taxol in Treating Ovarian Carcinoma and Its Effect on Complication Incidence.

Li P, Lou Y Evid Based Complement Alternat Med. 2024; 2021:2782875.

PMID: 38837981 PMC: 8709778. DOI: 10.1155/2021/2782875.

Regulation of secretory pathway kinase or kinase-like proteins in human cancers.

Du S, Zhu C, Ren X, Chen X, Cui X, Guan S Front Immunol. 2023; 14:942849.

PMID: 36825005 PMC: 9941534. DOI: 10.3389/fimmu.2023.942849.

FAM198B promotes colorectal cancer progression by regulating the polarization of tumor-associated macrophages via the SMAD2 signaling pathway.

Zheng X, Chen J, Nan T, Zheng L, Lan J, Jin X Bioengineered. 2022; 13(5):12435-12445.

PMID: 35587159 PMC: 9276016. DOI: 10.1080/21655979.2022.2075300.

The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.

Kazmierczak D, Jopek K, Sterzynska K, Nowicki M, Rucinski M, Januchowski R Int J Mol Sci. 2022; 23(1).

PMID: 35008952 PMC: 8745655. DOI: 10.3390/ijms23010526.

References

Rochman M, Malicet C, Bustin M . HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function. Biochim Biophys Acta. 2010; 1799(1-2):86-92. PMC: 2818475. DOI: 10.1016/j.bbagrm.2009.09.012. View

Jordan A, Hadfield J, Lawrence N, McGown A . Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev. 1998; 18(4):259-96. DOI: 10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u. View

Li D, Du X, Liu A, Li P . Suppression of nucleosome-binding protein 1 by miR-326 impedes cell proliferation and invasion in non-small cell lung cancer cells. Oncol Rep. 2015; 35(2):1117-24. DOI: 10.3892/or.2015.4403. View

Fletcher J, Haber M, Henderson M, Norris M . ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010; 10(2):147-56. DOI: 10.1038/nrc2789. View

Chen Y, Xiang H, Zhang Y, Wang J, Yu G . Loss of PCDH9 is associated with the differentiation of tumor cells and metastasis and predicts poor survival in gastric cancer. Clin Exp Metastasis. 2015; 32(5):417-28. DOI: 10.1007/s10585-015-9712-7. View

Tang C, Gao X, Liu H, Jiang T, Zhai X . Decreased expression of SEMA3A is associated with poor prognosis in gastric carcinoma. Int J Clin Exp Pathol. 2014; 7(8):4782-94. PMC: 4152039. View

Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M . MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013; 2013:241763. PMC: 3591129. DOI: 10.1155/2013/241763. View

Jiang N, Zhou L, Zhang X . Downregulation of the nucleosome-binding protein 1 (NSBP1) gene can inhibit the in vitro and in vivo proliferation of prostate cancer cells. Asian J Androl. 2010; 12(5):709-17. PMC: 3739312. DOI: 10.1038/aja.2010.39. View

Abdel-Rahman W, Lotsari-Salomaa J, Kaur S, Niskakoski A, Knuutila S, Jarvinen H . The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking β-Catenin/TCF Regulated Transcription. Gastroenterol Res Pract. 2016; 2016:6089658. PMC: 4800109. DOI: 10.1155/2016/6089658. View

10.

Zhang L, Han J, Jackson A, Clark L, Kilgore J, Guo H . NT1014, a novel biguanide, inhibits ovarian cancer growth in vitro and in vivo. J Hematol Oncol. 2016; 9(1):91. PMC: 5031332. DOI: 10.1186/s13045-016-0325-7. View

11.

Correia A, Bissell M . The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 2012; 15(1-2):39-49. PMC: 3658318. DOI: 10.1016/j.drup.2012.01.006. View

12.

Shi C, Zhang Z . Screening of potentially crucial genes and regulatory factors involved in epithelial ovarian cancer using microarray analysis. Oncol Lett. 2017; 14(1):725-732. PMC: 5494615. DOI: 10.3892/ol.2017.6183. View

13.

Yu S, Li A, Liu Q, Li T, Yuan X, Han X . Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017; 10(1):78. PMC: 5372296. DOI: 10.1186/s13045-017-0444-9. View

14.

Maione F, Molla F, Meda C, Latini R, Zentilin L, Giacca M . Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest. 2009; 119(11):3356-72. PMC: 2769187. DOI: 10.1172/JCI36308. View

15.

Januchowski R, Wojtowicz K, Zabel M . The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother. 2013; 67(7):669-80. DOI: 10.1016/j.biopha.2013.04.005. View

16.

Januchowski R, Sterzynska K, Zaorska K, Sosinska P, Klejewski A, Brazert M . Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016; 9(1):65. PMC: 5069986. DOI: 10.1186/s13048-016-0278-z. View

17.

Zhang W, Zhang Y, Zhang H, Fu Z, Ye J, Liu L . Expression of semaphorin 3A and neuropilin 1 with clinicopathological features and survival in human tongue cancer. Med Oral Patol Oral Cir Bucal. 2012; 17(6):e962-8. PMC: 3505717. DOI: 10.4317/medoral.18168. View

18.

Hennessy B, Coleman R, Markman M . Ovarian cancer. Lancet. 2009; 374(9698):1371-82. DOI: 10.1016/S0140-6736(09)61338-6. View

19.

Murphy W, Fossella F, Winn R, Shin D, HYNES H, Gross H . Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst. 1993; 85(5):384-8. DOI: 10.1093/jnci/85.5.384. View

20.

Maliepaard M, van Gastelen M, de Jong L, Pluim D, van Waardenburg R, Floot B . Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res. 1999; 59(18):4559-63. View